Literature DB >> 18772337

Hypoxia inducible factor-1alpha inactivation unveils a link between tumor cell metabolism and hypoxia-induced cell death.

Elena Favaro1, Giorgia Nardo, Luca Persano, Massimo Masiero, Lidia Moserle, Rita Zamarchi, Elisabetta Rossi, Giovanni Esposito, Mario Plebani, Ulrike Sattler, Thomas Mann, Wolfgang Mueller-Klieser, Vincenzo Ciminale, Alberto Amadori, Stefano Indraccolo.   

Abstract

Hypoxia and the acquisition of a glycolytic phenotype are intrinsic features of the tumor microenvironment. The hypoxia inducible factor-1alpha (HIF-1alpha) pathway is activated under hypoxic conditions and orchestrates a complex transcriptional program that enhances cell survival. Although the consequences of HIF-1alpha inactivation in cancer cells have been widely investigated, only a few studies have addressed the role of HIF-1alpha in the survival of cancer cells endowed with different glycolytic capacities. In this study, we investigated this aspect in ovarian cancer cells. Hypoxia-induced toxicity was increased in highly glycolytic cells compared with poorly glycolytic cells; it was also associated with a sharp decrease in intracellular ATP levels and was prevented by glucose supplementation. Stable HIF-1alpha silencing enhanced hypoxia-induced cell death in vitro due to a lack of cell cycle arrest. Tumors bearing attenuated HIF-1alpha levels had similar growth rates and vascularization as did controls, but tumors showed higher proliferation levels and increased necrosis. Moreover, tumors formed by HIF-1alpha deficient cells had higher levels of lactate and lower ATP concentrations than controls as shown by metabolic imaging. The findings that such metabolic properties can affect the survival of cancer cells under hypoxic conditions and that these properties contribute to the determination of the consequences of HIF-1alpha inactivation could have important implications on the understanding of the effects of anti-angiogenic and HIF-1alpha-targeting drugs in cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18772337      PMCID: PMC2543085          DOI: 10.2353/ajpath.2008.071183

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  55 in total

1.  Hypoxia-inducible factor 1 alpha (HIF-1 alpha) gene expression in human ovarian carcinoma.

Authors:  Kentaro Nakayama; Atsuko Kanzaki; Kohkichi Hata; Hidetaka Katabuchi; Hitoshi Okamura; Kohji Miyazaki; Manabu Fukumoto; Yuji Takebayashi
Journal:  Cancer Lett       Date:  2002-02-25       Impact factor: 8.679

2.  Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy.

Authors:  P Birner; M Schindl; A Obermair; G Breitenecker; G Oberhuber
Journal:  Clin Cancer Res       Date:  2001-06       Impact factor: 12.531

3.  Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography.

Authors:  Reinhard Bos; Jacobus J M van Der Hoeven; Elsken van Der Wall; Petra van Der Groep; Paul J van Diest; Emile F I Comans; Urvi Joshi; Gregg L Semenza; Otto S Hoekstra; Adriaan A Lammertsma; Carla F M Molthoff
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

4.  Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth.

Authors:  H E Ryan; M Poloni; W McNulty; D Elson; M Gassmann; J M Arbeit; R S Johnson
Journal:  Cancer Res       Date:  2000-08-01       Impact factor: 12.701

Review 5.  Hypoxia-inducible factors and hypoxic cell death in tumour physiology.

Authors:  Andrea L Bacon; Adrian L Harris
Journal:  Ann Med       Date:  2004       Impact factor: 4.709

6.  Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation.

Authors:  Oliver Stoeltzing; Marya F McCarty; Jane S Wey; Fan Fan; Wenbiao Liu; Anna Belcheva; Corazon D Bucana; Gregg L Semenza; Lee M Ellis
Journal:  J Natl Cancer Inst       Date:  2004-06-16       Impact factor: 13.506

Review 7.  Lactate in solid malignant tumors: potential basis of a metabolic classification in clinical oncology.

Authors:  S Walenta; T Schroeder; W Mueller-Klieser
Journal:  Curr Med Chem       Date:  2004-08       Impact factor: 4.530

Review 8.  The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis.

Authors:  A E Greijer; E van der Wall
Journal:  J Clin Pathol       Date:  2004-10       Impact factor: 3.411

Review 9.  Experience with bevacizumab in the management of epithelial ovarian cancer.

Authors:  Robert A Burger
Journal:  J Clin Oncol       Date:  2007-07-10       Impact factor: 44.544

10.  Effect of VEGF receptor-2 antibody on vascular function and oxygenation in spontaneous and transplanted tumors.

Authors:  Bruce M Fenton; Scott F Paoni; Ivan Ding
Journal:  Radiother Oncol       Date:  2004-08       Impact factor: 6.280

View more
  17 in total

1.  Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro.

Authors:  Dave N T Aryee; Stephan Niedan; Maximilian Kauer; Raphaela Schwentner; Idriss M Bennani-Baiti; Jozef Ban; Karin Muehlbacher; Michael Kreppel; Robert L Walker; Paul Meltzer; Christopher Poremba; Reinhard Kofler; Heinrich Kovar
Journal:  Cancer Res       Date:  2010-05-04       Impact factor: 12.701

2.  NHERF1/EBP50 in Breast Cancer: Clinical Perspectives.

Authors:  Antonia Bellizzi; Andrea Malfettone; Rosa A Cardone; Anita Mangia
Journal:  Breast Care (Basel)       Date:  2010-04-09       Impact factor: 2.860

Review 3.  The role of ¹⁸F-FDG PET imaging in upper gastrointestinal malignancies.

Authors:  Tong Dai; Elizabeta Popa; Manish A Shah
Journal:  Curr Treat Options Oncol       Date:  2014-09

4.  Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids.

Authors:  Jesper Kolenda; Stine Skov Jensen; Charlotte Aaberg-Jessen; Karina Christensen; Claus Andersen; Nils Brünner; Bjarne Winther Kristensen
Journal:  J Neurooncol       Date:  2010-09-11       Impact factor: 4.130

5.  Hypoxia inducible factor 1α promotes survival of mesenchymal stem cells under hypoxia.

Authors:  Bingke Lv; Feng Li; Jie Fang; Limin Xu; Chengmei Sun; Jianbang Han; Tian Hua; Zhongfei Zhang; Zhiming Feng; Xiaodan Jiang
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

6.  Interaction of hypoxia-inducible factor-1α and Notch signaling regulates medulloblastoma precursor proliferation and fate.

Authors:  Francesca Pistollato; Elena Rampazzo; Luca Persano; Sara Abbadi; Chiara Frasson; Luca Denaro; Domenico D'Avella; David M Panchision; Alessandro Della Puppa; Renato Scienza; Giuseppe Basso
Journal:  Stem Cells       Date:  2010-11       Impact factor: 6.277

7.  Human cancers converge at the HIF-2alpha oncogenic axis.

Authors:  Aleksandra Franovic; Chet E Holterman; Josianne Payette; Stephen Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-02       Impact factor: 11.205

8.  Manipulation of tumor metabolism for therapeutic approaches: ovarian cancer-derived cell lines as a model system.

Authors:  Kristina Goetze; Christian G Fabian; Andrea Siebers; Livia Binz; Daniel Faber; Stefano Indraccolo; Giorgia Nardo; Ulrike G A Sattler; Wolfgang Mueller-Klieser
Journal:  Cell Oncol (Dordr)       Date:  2015-08-19       Impact factor: 6.730

9.  STAT3 silencing inhibits glioma single cell infiltration and tumor growth.

Authors:  Maike Priester; Ekaterini Copanaki; Vida Vafaizadeh; Sandra Hensel; Christian Bernreuther; Markus Glatzel; Volker Seifert; Bernd Groner; Donat Kögel; Jakob Weissenberger
Journal:  Neuro Oncol       Date:  2013-03-13       Impact factor: 12.300

10.  Design and in vitro activities of N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl)methyl]heteroarylsulfonamides, novel, small-molecule hypoxia inducible factor-1 pathway inhibitors and anticancer agents.

Authors:  Jiyoung Mun; Adnan Abdul Jabbar; Narra Sarojini Devi; Shaoman Yin; Yingzhe Wang; Chalet Tan; Deborah Culver; James P Snyder; Erwin G Van Meir; Mark M Goodman
Journal:  J Med Chem       Date:  2012-07-24       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.